Theriva Biologics, Inc. Increase Decrease In Operating Lease Liability
Theriva Biologics, Inc. (TOVX) reported Increase Decrease In Operating Lease Liability of -$278.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Theriva Biologics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$122.00K.
- Theriva Biologics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$156.00K.
- Theriva Biologics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$149.00K.
- Theriva Biologics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$145.00K.
- Theriva Biologics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$562.00K.
- Theriva Biologics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$482.00K.
- Theriva Biologics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$422.00K.
- Theriva Biologics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$124.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$278.00K 10-Q · filed 2026-08-11 | -$427.00K derived: sum of 3 quarters · filed 2026-08-11 | -$572.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$156.00K 10-Q · filed 2026-05-05 | -$305.00K derived: sum of 2 quarters · filed 2026-05-05 | -$450.00K derived: sum of 3 quarters · filed 2026-05-05 | -$588.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$294.00K derived: sum of 2 quarters · filed 2026-03-12 | -$432.00K derived: sum of 3 quarters · filed 2026-08-11 | -$562.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$283.00K derived: sum of 2 quarters · filed 2026-08-11 | -$413.00K 10-Q · filed 2025-11-12 | -$538.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$268.00K 10-Q · filed 2026-08-11 | -$393.00K derived: sum of 3 quarters · filed 2026-08-11 | -$516.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$130.00K 10-Q · filed 2026-05-05 | -$255.00K derived: sum of 2 quarters · filed 2026-05-05 | -$378.00K derived: sum of 3 quarters · filed 2026-05-05 | -$497.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$248.00K derived: sum of 2 quarters · filed 2026-03-12 | -$367.00K derived: sum of 3 quarters · filed 2026-03-12 | -$482.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$123.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$242.00K derived: sum of 2 quarters · filed 2025-11-12 | -$357.00K 10-Q · filed 2025-11-12 | -$467.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$234.00K 10-Q · filed 2025-08-11 | -$344.00K derived: sum of 3 quarters · filed 2025-08-11 | -$451.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$115.00K 10-Q · filed 2025-05-14 | -$225.00K derived: sum of 2 quarters · filed 2025-05-14 | -$332.00K derived: sum of 3 quarters · filed 2025-05-14 | -$437.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$217.00K derived: sum of 2 quarters · filed 2025-03-06 | -$322.00K derived: sum of 3 quarters · filed 2025-03-06 | -$422.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | -$107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$212.00K derived: sum of 2 quarters · filed 2024-11-12 | -$312.00K 10-Q · filed 2024-11-12 | -$309.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$205.00K 10-Q · filed 2024-08-13 | -$202.00K derived: sum of 3 quarters · filed 2024-08-13 | -$228.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$100.00K 10-Q · filed 2024-05-07 | -$97.00K derived: sum of 2 quarters · filed 2024-05-07 | -$123.00K derived: sum of 3 quarters · filed 2024-05-07 | -$175.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$23.00K derived: sum of 2 quarters · filed 2024-03-25 | -$75.00K derived: sum of 3 quarters · filed 2024-03-25 | -$124.00K 10-K · filed 2024-03-25 |
| 2022-09-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$78.00K derived: sum of 2 quarters · filed 2023-11-13 | -$127.00K 10-Q · filed 2023-11-13 | -$175.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$101.00K 10-Q · filed 2023-08-08 | -$149.00K derived: sum of 3 quarters · filed 2023-08-08 | -$196.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$49.00K 10-Q · filed 2023-05-11 | -$97.00K derived: sum of 2 quarters · filed 2023-05-11 | -$144.00K derived: sum of 3 quarters · filed 2023-05-11 | -$197.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$95.00K derived: sum of 2 quarters · filed 2023-03-30 | -$148.00K derived: sum of 3 quarters · filed 2023-03-30 | -$216.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$100.00K derived: sum of 2 quarters · filed 2022-11-10 | -$168.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$121.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$68.00K 10-Q · filed 2022-05-16 | |||
| 2020-09-30 | -$183.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |